Hypothesis

Rapamycin triggers a self‑sustaining lysosomal‑mitochondrial epigenetic program that remains active after drug clearance, thereby extending lifespan through genuine cellular remodeling rather than mere starvation mimickry.

Mechanistic rationale

• mTORC1 inhibition promotes TFEB translocation to the lysosomal surface, driving lysosomal biogenesis and autophagic flux.[2]
• Heightened lysosomal activity increases intracellular acetyl‑CoA via enhanced catabolism of lipids and amino acids, supplying a key substrate for histone acetyltransferases.
• Elevated histone acetylation, especially H3K27ac at enhancer regions of the PPARGC1A (PGC‑1α) locus, stabilizes a transcriptional program that maintains mitochondrial oxidative capacity, ROS detoxification, and fatty‑acid oxidation.[3]
• This creates a bistable epigenetic lock: once established, the mitochondrial‑lysosomal axis remains active even when mTOR signaling returns to baseline, mimicking a durable adaptive state rather than a transient stress response.

Testable predictions

1. Persistent lysosomal and mitochondrial markers – Mice receiving intermittent rapamycin (4 weeks on, 2 weeks off) will retain elevated lysosomal protein levels (LAMP1, CTSB) and higher basal oxygen consumption rates (OCR) in skeletal muscle and liver for at least two weeks after the final dose, compared with vehicle‑treated and pair‑fed caloric‑restriction controls.
2. Enduring histone acetylation at PGC‑1α enhancers – ChIP‑seq for H3K27ac on liver tissue will show significantly increased enrichment at known PGC‑1α enhancer regions in rapamycin‑treated mice, and this enrichment will persist after drug withdrawal, whereas global H3K27ac levels remain unchanged.
3. TFEB dependency – Conditional hepatocytes‑specific TFEB knockdown during rapamycin exposure will abolish the persistent lysosomal biogenesis, the downstream increase in acetyl‑CoA, and the maintained mitochondrial OCR, confirming TFEB as the upstream trigger of the epigenetic lock.
4. Metabolic flux confirmation – Targeted metabolomics will reveal a sustained rise in hepatic acetyl‑CoA and NAD⁺/NADH ratio after rapamycin cessation, correlating with the observed histone acetylation changes.
5. Chromatin accessibility – ATAC‑seq will demonstrate increased open chromatin at PGC‑1α enhancers in rapamycin‑withdrawn mice, linking acetylation to a transcription‑permissive state.

Falsifiability

If rapamycin withdrawal leads to a rapid return (within 48 h) of lysosomal and mitochondrial parameters to pretreatment levels, and no lasting changes in H3K27ac at PGC‑1α enhancers or acetyl‑CoA concentrations are detectable, then the proposed epigenetic lock does not exist and the hypothesis is refuted. Conversely, observation of any of the predicted persistent changes would support the notion that rapamycin confers longevity via a genuine, self‑maintaining remodeling of cellular homeostasis rather than merely imitating a harder life.